Blood-based test can predict risk of developing symptoms of Alzheimer's up to a decade early

Article excerpt

A blood test for the biomarker phosphorylated tau 217 (p-tau217) recently received federal clearance, but questions have emerged about the extent to which such tests can accurately predict whether a cognitively healthy individual will develop cognitive impairment, a key symptom of Alzheimer's disease.